2nd How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
Chairs: Ulrich Jäger, Marie José Kersten, Loretta Nastoupil

2nd How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
Information
ABOUT THE CONFERENCE:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies will also be discussed.
The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, ensuring a maximum level of interaction between faculty and registered participants. In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, regulatory authorities and industry.
SCIENTIFIC TOPICS:
• Non-hodgkin lymphoma (NHL)
• Multiple myeloma
• Novel indications CAR T-cell therapy
• Managing toxicity of CAR-T and bispecific antibody treatment
• Real world data CAR-T
• Life after CAR T-cell therapy
Programme
Read the final programme!



